title: Dopamine 2 and somatostatin 1-5 receptors coexpression in clinically non-functioning pituitary adenomas.
abstract: This study investigated quantitated expression of dopamine 2 receptor (D2R) and somatostatin receptors of the five types (SSTR1-SSTR5) in a large series of clinically non-functioning pituitary adenomas (CNFAs). Co-expression of these receptors in individual adenomas was studied as well as correlation between receptor types. Adenoma tissue from 198 patients who underwent surgery for CNFAs was analyzed by immunohistochemistry and quantitative real-time PCR. D2R and SSTR1-3 mRNA was expressed in all 198 adenomas. SSTR4 and SSTR5 were detectable in 85 % and 61 % of adenomas, respectively. Expression of D2R was significantly higher than that of the somatostatin receptors. The median relative expressions were as follows from highest D2R >> SSTR3 > SSTR2 > SSTR1 > SSTR5 > SSTR4. High relative expression (ratio to beta-glucuronidase mRNA > 1) of D2R was found in 60 % of tumors, high expression of SSTR1 in 7.5 %, SSTR2 in 7 %, SSTR3 in 4 % and SSTR5 in 0.5 %. The quantity of D2R correlated positively with expression of SSTR2 and SSTR3, and negatively with SSTR1 and SSTR5. Among histological adenoma types, SSTR1 was significantly higher in null-cell adenomas and SSTR3 was lower in silent corticotroph adenomas. In conclusions, in CNFAs, high expression of somatostatin receptors is much less common than that of D2R, and co-expression of both these receptors is exceptional. D2R and SSTR3 seem to be the most promising targets for pharmacological treatment.
authors.affiliation: Fourth Department of Internal Medicine - Hematology, Institute of Clinical Biochemistry and Diagnostics, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic. beranek@lfhk.cuni.cz.
authors.forename: F
authors.initials: F
authors.lastname: Gabalec
authors.forename: M
authors.initials: M
authors.lastname: Drastikova
authors.forename: T
authors.initials: T
authors.lastname: Cesak
authors.forename: D
authors.initials: D
authors.lastname: Netuka
authors.forename: V
authors.initials: V
authors.lastname: Masopust
authors.forename: J
authors.initials: J
authors.lastname: Machac
authors.forename: J
authors.initials: J
authors.lastname: Marek
authors.forename: J
authors.initials: J
authors.lastname: Cap
authors.forename: M
authors.initials: M
authors.lastname: Beranek
mesh_terms: D000236:Adenoma / Q000378:metabolism*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000378:metabolism*; D010911:Pituitary Neoplasms / Q000378:metabolism*; D017448:Receptors, Dopamine D2 / Q000378:metabolism*; D017481:Receptors, Somatostatin / Q000378:metabolism*
chemical_list: D009363:Neoplasm Proteins; D017448:Receptors, Dopamine D2; D017481:Receptors, Somatostatin